0001193125-22-206851.txt : 20220729 0001193125-22-206851.hdr.sgml : 20220729 20220729171810 ACCESSION NUMBER: 0001193125-22-206851 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 24 CONFORMED PERIOD OF REPORT: 20220727 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220729 DATE AS OF CHANGE: 20220729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 221121879 BUSINESS ADDRESS: STREET 1: 2445 TECHNOLOGY FOREST BLVD. STREET 2: SUITE 1100 CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 2445 TECHNOLOGY FOREST BLVD. STREET 2: SUITE 1100 CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE DATE OF NAME CHANGE: 20070426 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 8-K 1 d342123d8k.htm 8-K 8-K
false 0001062822 0001062822 2022-07-27 2022-07-27

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 27, 2022

 

 

Lexicon Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-30111   76-0474169
(State or other jurisdiction of
incorporation or organization)
  (Commission
File Number)
  (IRS Employer
Identification Number)

2445 Technology Forest Blvd., 11th Floor

The Woodlands, Texas 77381

(Address of principal executive offices and Zip Code)

(281) 863-3000

(Registrant’s telephone number, including area code)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
symbol(s)

 

Name of each exchange
on which registered

Common stock, par value $0.001   LXRX   The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 1.01

Entry into a Material Definitive Agreement

Underwriting Agreement

On July 27, 2022, Lexicon Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc. and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), relating to a public offering (the “Offering”) of 16,843,600 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”).

The price to the public for the Shares in the Offering was $2.50 per Share. In addition, under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 2,526,540 shares of Common Stock (the “Option Shares”) at the same price per share as the Shares. The net proceeds to the Company from the Offering are expected to be approximately $39.3 million (or approximately $45.2 million if the Underwriters exercise their option to purchase the Option Shares in full), in each case, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company and customary conditions to closing, obligations of the parties and termination provisions. Additionally, the Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). The Company has also agreed with the Underwriters not to offer or sell any shares of its Common Stock (or securities convertible into or exchangeable for Common Stock), subject to certain exceptions, for a period of 60 days after the date of the Underwriting Agreement without the prior written consent of Citigroup Global Markets Inc.

The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-258564) (the “Registration Statement”), declared effective by the Securities and Exchange Commission on September 14, 2021, and a related prospectus included in the Registration Statement, as supplemented by a preliminary prospectus supplement dated July 27, 2022 and a final prospectus supplement dated July 27, 2022.

The foregoing summary of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, which is attached to this Current Report on Form 8-K (this “Current Report”) as Exhibit 1.1, and which is incorporated herein by reference. Vinson & Elkins L.L.P., counsel to the Company, delivered an opinion as to the legality of the issuance and sale of the Shares in the Offering, a copy of which is attached hereto as Exhibit 5.1 and is incorporated herein by reference.

Purchase Agreements

On July 27, 2022, the Company entered into (i) a purchase agreement (the “Artal Purchase Agreement”) with Artal International S.C.A., Artal Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P. (“Invus”), Mr. Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A. and (ii) a purchase agreement with Invus US Partners LLC (the “Invus Purchase Agreement” and together with the Artal Purchase Agreement, the “Purchase Agreements”) for purposes of waiving certain preemptive rights.

Pursuant to the Purchase Agreements, two affiliates of Invus (the “Private Placement Purchasers”) have agreed to purchase, and the Company has agreed to issue to the Private Placement Purchasers on the closing date of the Offering, 17,156,400 shares of Common Stock at a price per share equal to the price per share to the public in the Offering (the “Private Placement”). The total purchase price shall be equal to approximately $42.9 million. The Private Placement Purchasers will have the option to purchase, on a pro rata basis, up to an additional 2,573,460 shares of Common Stock to the extent the Underwriters exercise their option to purchase the Option Shares.

The Purchase Agreements incorporate the representations and warranties and covenants made by the Company in the Underwriting Agreement for the benefit of the Private Placement Purchasers and certain of their affiliates. It also contains customary conditions to closing, obligations of the parties and termination provisions.

 

 

2


The Artal Purchase Agreement and the Invus Purchase Agreement are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report and are incorporated herein by reference. The description of the Purchase Agreements in this Current Report is a summary and is qualified in its entirety by the terms of the Purchase Agreements.

Relationships

After the Offering and the Private Placement, Invus and its affiliates will hold approximately the same percentage of the Company’s outstanding Common Stock as they did before the Offering and the Private Placement.

 

Item 3.02

Unregistered Sales of Equity Securities.

The information set forth under “Purchase Agreements” in Item 1.01 of this Current Report is hereby incorporated in this Item 3.02 by reference. The Private Placement will be taken in reliance upon the exemption from the registration requirements of the Securities Act provided by Section 4(a)(2) thereof.

 

Item 7.01

Regulation FD Disclosure.

On July 27, 2022, the Company issued a press release announcing the launch of the Offering. A copy of the press release relating to the launch of the Offering is furnished as Exhibit 99.1 to this Current Report.

On July 28, 2022, the Company issued a press release announcing the pricing of the Offering. A copy of the press release relating to the pricing of the Offering is furnished as Exhibit 99.2 to this Current Report.

In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 7.01 or Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information furnished pursuant to Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely to satisfy the requirements of Regulation FD.

 

Item 8.01

Other Events

On July 27, 2022, the Company issued a press release announcing that the U.S. Food and Drug Administration accepted for review and filed our New Drug Application for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of heart failure. A copy of the press release relating to the announcement is attached hereto as Exhibit 99.3 and incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits

(d)    Exhibits.

 

Exhibit

Number

  

Description

  1.1

   Underwriting Agreement, dated as of July 27, 2022, by and among Lexicon Pharmaceuticals, Inc. and Citigroup Global Markets Inc. and Piper Sandler & Co., as representatives of the several underwriters named therein.

  5.1

   Opinion of Vinson & Elkins L.L.P.

10.1

   Purchase Agreement, dated as of July 27, 2022, among Lexicon Pharmaceuticals, Inc. and Artal International S.C.A., Artal Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A.

10.2

   Purchase Agreement, dated as of July 27, 2022, among Lexicon Pharmaceuticals, Inc. and Invus US Partners LLC.

 

3


Exhibit
Number

  

Description

23.1    Consent of Vinson & Elkins L.L.P. (included in Exhibit 5.1).
99.1    Press Release, dated July 27, 2022.
99.2    Press Release, dated July 28, 2022.
99.3    Press Release, dated July 27, 2022.
EX-104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

4


Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Lexicon Pharmaceuticals, Inc.
Date: July 29, 2022     By:  

/s/ Brian T. Crum

      Brian T. Crum
      Senior Vice President and General Counsel

 

5

EX-1.1 2 d342123dex11.htm EX-1.1 EX-1.1

Exhibit 1.1

LEXICON PHARMACEUTICALS, INC.

16,843,600 Shares

Common Stock

($0.001 par value)

Underwriting Agreement

July 27, 2022

Citigroup Global Markets Inc.

Piper Sandler & Co.

As Representatives of the several Underwriters

 

c/o

Citigroup Global Markets Inc.

 

388 Greenwich Street

 

New York, New York 10013

 

c/o

Piper Sandler & Co.

 

800 Nicollet Mall

 

Minneapolis, Minnesota 55402

Ladies and Gentlemen:

Lexicon Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.001 par value (“Common Stock”) of the Company set forth in Schedule I hereto (the “Shares”) (said Shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto (the “Option Securities;” the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.

As used in this underwriting agreement (this “Agreement”), the “Registration Statement” means the registration statement referred to in paragraph 1(a) hereof, including the exhibits, schedules and financial statements and any prospectus supplement relating to the Securities that is filed with the Securities and Exchange Commission (the “SEC”) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “Securities Act”) and deemed part of such registration statement pursuant to Rule 430B under the Securities Act, as amended on each Effective Date, and, in the event any post-effective amendment thereto or any registration statement and any amendments thereto filed pursuant to Rule 462(b) under the Securities Act (a “Rule 462(b) Registration Statement”) becomes effective prior to the Closing Date (as defined in Section 3 hereof), shall also mean such registration statement as so amended or such Rule 462(b) Registration Statement, as the


case may be; the “Effective Date” means each date and time that the Registration Statement, any post-effective amendment or amendments thereto or any Rule 462(b) Registration Statement became or becomes effective; the “Base Prospectus” means the base prospectus referred to in paragraph 1(a) hereof contained in the Registration Statement at the date and time that this Agreement is executed and delivered by the parties hereto (the “Execution Time”); the “Preliminary Prospectus Supplement” means any preliminary prospectus supplement to the Base Prospectus referred to in paragraph 1(a) hereof which is used prior to the filing of the Final Prospectus Supplement, together with the Base Prospectus; and the “Final Prospectus Supplement” means the prospectus supplement relating to the Securities that is first filed pursuant to Rule 424(b) under the Securities Act (“Rule 424(b)”) after the Execution Time, together with the Base Prospectus.

Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”) on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be; and any reference herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be, deemed to be incorporated therein by reference.

As used in this Agreement, the “Pricing Disclosure Package” shall mean (i) the Base Prospectus, (ii) the Preliminary Prospectus Supplement used most recently prior to the Execution Time, (iii) any issuer free writing prospectus, as defined in Rule 433 under the Securities Act (an “Issuer Free Writing Prospectus”), identified in Schedule III hereto, and (iv) any other free writing prospectus, as defined in Rule 405 under the Securities Act (a “Free Writing Prospectus”), that the parties hereto shall hereafter expressly agree in writing to treat as part of the Pricing Disclosure Package.

1. Representations and Warranties. The Company represents and warrants to, and agrees with, each Underwriter as set forth below in this Section 1.

(a) The Company meets the requirements for use of Form S-3 under the Securities Act and has prepared and filed with the SEC a shelf registration statement, as defined in Rule 405 (file number 333-258564) on Form S-3, including a related Base Prospectus, for registration under the Securities Act of the offering and sale of the Shares. The Company may have filed one or more amendments thereto, including any Preliminary Prospectus Supplement, each of which has previously been furnished to you and has become effective upon filing. The Company will next file with the SEC a Final Prospectus Supplement relating to the Shares in accordance with Rule 424(b). As filed, such Final Prospectus Supplement shall contain all information required by the Securities Act and the rules thereunder and, except to the extent the Representatives shall agree in

 

2


writing to a modification, shall be in all substantive respects in the form furnished to you prior to the Execution Time or, to the extent not completed at the Execution Time, shall contain only such specific additional information and other changes (beyond that contained in the Base Prospectus and any Preliminary Prospectus Supplement) as the Company has advised you, prior to the Execution Time, will be included or made therein. The Registration Statement, at the Execution Time, is effective and meets the requirements set forth in Rule 415(a)(1)(x). There is no order preventing or suspending the use of the Registration Statement, the Pricing Disclosure Package or the Final Prospectus Supplement, and, to the knowledge of the Company, no proceeding for that purpose or pursuant to Section 8A of the Securities Act against the Company or related to the offering has been initiated or threatened by the SEC and no notice of objection of the SEC to the use of such Registration Statement pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company. Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be; and any reference herein to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement, the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement shall be deemed to refer to and include the filing of any document under the Exchange Act after the Effective Date of the Registration Statement or the issue date of the Base Prospectus, any Preliminary Prospectus Supplement or the Final Prospectus Supplement, as the case may be, deemed to be incorporated therein by reference.

(b) On each Effective Date, the Registration Statement did, and when the Final Prospectus Supplement is first filed in accordance with Rule 424(b) and on the Closing Date, the Final Prospectus Supplement (and any amendment or supplement thereto) will, comply in all material respects with the applicable requirements of the Securities Act and the Exchange Act and the respective rules thereunder; on each Effective Date, at the Execution Time, and on the Closing Date, the Registration Statement did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading; and on the date of any filing pursuant to Rule 424(b) and on the Closing Date, the Final Prospectus Supplement (together with any amendment or supplement thereto) will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no representations or warranties as to the information contained in or omitted from the Registration Statement or the Final Prospectus Supplement (or any amendment or supplement thereto) in reliance upon and in conformity with information furnished in writing to the Company by the Underwriters specifically for inclusion in the Registration Statement or the Final Prospectus Supplement (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Underwriters consists of the information described as such in Section 8(b) hereof.

 

3


(c) As of the Execution Time, the Pricing Disclosure Package, when taken together as a whole with the pricing information set forth in Schedule I hereto, and each electronic road show, when taken together as a whole with the pricing information set forth in Schedule I hereto, does not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The preceding sentence does not apply to statements in or omissions from the Pricing Disclosure Package based upon and in conformity with written information furnished to the Company by the Underwriters specifically for use therein, it being understood and agreed that the only such information furnished by or on behalf of the Underwriters consists of the information described as such in Section 8(b) hereof.

(d) (i) At the earliest time after the filing of the Registration Statement that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2)) of the Shares and (ii) as of the Execution Time (with such date being used as the determination date for purposes of this clause (ii)), the Company was not and is not an Ineligible Issuer (as defined in Rule 405), without taking account of any determination by the SEC pursuant to Rule 405 that it is not necessary that the Company be considered an Ineligible Issuer.

(e) The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date.

(f) Prior to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any of the Shares by means of any “prospectus” (within the meaning of the Securities Act) or used any “prospectus” (within the meaning of the Securities Act) in connection with the offer or sale of the Shares, in each case other than the Registration Statement, any Preliminary Prospectus Supplement and the Final Prospectus Supplement. The Company represents and agrees that it has not and, unless it obtains the prior consent of the Underwriters, it will not make any offer relating to the Shares that would constitute an “Issuer Free Writing Prospectus” or that would otherwise constitute a “Free Writing Prospectus” other than any Permitted Free Writing Prospectus. Any such Free Writing Prospectus relating to the Shares consented to by the Representatives is hereinafter referred to as a “Permitted Free Writing Prospectus.” The Company has complied and will comply in all material respects with the requirements of Rule 433 under the Securities Act applicable to any Permitted Free Writing Prospectus, including timely filing with the SEC where required, legending and record keeping. Each Permitted Free Writing Prospectus does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package did not and on the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no representations or warranties as to the information contained in or omitted from such Permitted Free Writing Prospectus in reliance upon and in conformity with information furnished in writing to the Company by the Underwriters specifically for inclusion in such Permitted Free Writing Prospectus, it being understood and agreed that the only such information furnished by the Underwriters consists of the information described as such in Section 8(b) hereof.

 

4


(g) All statistical, demographic and market-related data included in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects or represent the Company’s good faith estimates that are made on the basis thereof. To the extent required, the Company has obtained the written consent for the use of such data from such sources.

(h) The Company has established and maintains “disclosure controls and procedures” (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company’s principal executive officer and its principal financial or accounting executive officer by others within those entities, within the time periods specified in the SEC’s rules and forms; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Company’s most recent fiscal quarter; and (iii) are effective in all material respects to perform the functions for which they were established. Since the end of the Company’s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company’s internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting

(i) This Agreement has been duly authorized, executed and delivered by the Company.

(j) (i) The Company’s authorized equity capitalization is as set forth in the Pricing Disclosure Package and the Final Prospectus Supplement; (ii) the capital stock of the Company conforms in all respects to the description thereof contained in the Pricing Disclosure Package and the Final Prospectus Supplement; (iii) the outstanding shares of Common Stock have been duly and validly authorized and issued and are fully paid and nonassessable; (iv) the Shares have been duly and validly authorized and, when issued and delivered to and paid for by the Underwriters pursuant to this Agreement, will be fully paid and nonassessable; (v) the Securities in book-entry form are in valid and sufficient form; (vi) the holders of outstanding shares of capital stock of the Company are not entitled to preemptive or other rights to subscribe for the Securities, except for any such rights as have been effectively waived or satisfied; and, (vii) except as set forth in the Pricing Disclosure Package and the Final Prospectus Supplement, no options, warrants or other rights to purchase, agreements or other obligations to issue, or rights to convert any obligations into or exchange any securities for, shares of capital stock of or ownership interests in the Company are outstanding.

 

5


(k) There is no material agreement required to be described in the Registration Statement or incorporated therein, or to be filed as an exhibit thereto, which is not described or filed as required (and the Preliminary Prospectus Supplement contains in all material respects the same description of the foregoing matters contained in the Final Prospectus Supplement).

(l) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, there are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived.

(m) Subsequent to the respective dates as of which information is given in the Registration Statement and the Final Prospectus Supplement: (i) there has been no material adverse change, or any development that could be reasonably expected to result in a material adverse change, in (A) the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B) the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a “Material Adverse Change”); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business; and (iii) there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company’s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.

(n) Ernst & Young LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the SEC as a part of the Registration Statement, the Base Prospectus and the Final Prospectus Supplement, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.

 

6


(o) The financial statements filed with the SEC as a part of the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement comply as to form in all material respects with the requirements of Regulation S-X under the Securities Act and present fairly in all material respects the consolidated financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations, changes in stockholders’ equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement fairly presents the information called for in all material respects and has been prepared in accordance with the SEC’s rules and guidelines applicable thereto in all material respects. No other financial statements or supporting schedules are required to be included in the Registration Statement, the Pricing Disclosure Package or the Final Prospectus Supplement.

(p) The Company and each of its subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement fairly presents the information called for in all material respects and is prepared in accordance with the SEC’s rules and guidelines applicable thereto.

(q) The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of Texas and each other jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change.

 

7


(r) Each of the Company’s “subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. Each of the Company’s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company’s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and, except as otherwise disclosed in the Final Prospectus Supplement, are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation, association or other entity that would constitute a significant subsidiary as defined under Rule 1-02 of Regulation S-X other than the subsidiaries listed in Exhibit 21 to the Company’s most recent Annual Report on Form 10-K.

(s) The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement under the caption “Capitalization” (other than for subsequent issuances, if any, pursuant to employee benefit plans or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement and the Final Prospectus Supplement). The Common Stock (including the Shares) conform in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement. All of the issued and outstanding Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding Common Stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement.

(t) The Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and are listed on the Nasdaq Global Select Market (“Nasdaq”), and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any notification that the SEC or Nasdaq is contemplating terminating such registration or listing. To the Company’s knowledge, it is in compliance in all material respects with all applicable listing requirements of Nasdaq.

 

8


(u) Neither the Company nor any of its subsidiaries is in violation of its charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (“Default”) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject, except for such Defaults as could not be expected, individually or in the aggregate, to result in a Material Adverse Change. The Company’s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and the issuance and sale of the Shares will not contravene (i) the provisions of the charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary, (ii) any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, and (iii) any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries; except, in the case of clauses (ii) and (iii), as would not reasonably be expected to result in a Material Adverse Change.

(v) Neither the issue and sale of the Securities nor the consummation of any other of the transactions contemplated by this Agreement, nor the execution, delivery and performance of this Agreement by the Company, nor the fulfillment of the terms hereof will conflict with, result in a breach or violation of, or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, (i) the charter or bylaws of the Company or any of its subsidiaries, (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company or any of its subsidiaries is a party or bound or to which its or their property is subject, or (iii) any statute, law, rule, regulation, judgment, order or decree applicable to the Company or any of its subsidiaries of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or any of its subsidiaries or any of its or their properties, except in the case of clauses (ii) and (iii) for any such breach, violation or imposition as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change and as would not materially adversely affect the ability of the Underwriters to consummate the transactions contemplated by this Agreement.

(w) The historical financial statements of the Company included in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement present fairly in all material respects the financial condition, results of operations and cash flows of the Company as of the dates and for the periods indicated, comply as to form in all material respects with the applicable accounting requirements of the Securities Act and have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved.

 

9


(x) Each of the Company and each of its subsidiaries owns or leases all such properties as are necessary to the conduct of its operations as presently conducted, except as would not reasonably be expected to have a Material Adverse Change.

(y) There is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company exists, except as described in the Final Prospectus Supplement, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could result in a Material Adverse Change.

(z) The Company and its subsidiaries own, or have rights to use the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as being owned or licensed by them or which are used in and necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, “Intellectual Property”) and, to the Company’s knowledge, the conduct of their respective businesses does not and will not infringe or misappropriate in any material respect any such rights of others. The Intellectual Property owned by the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the Company’s knowledge: (i) except as otherwise disclosed in the Final Prospectus Supplement and with respect to LX9211 (to which the Company owns an exclusive license), there are no third parties who have ownership, royalty, or exclusive license rights to any Intellectual Property owned by the Company, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as licensed to the Company or one or more of its subsidiaries; and (ii) there is no material infringement by third parties of any Intellectual Property owned by the Company. There is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company’s rights in or to any Intellectual Property licensed to the Company; (B) challenging the validity, enforceability or scope of any Intellectual Property owned by the Company; or (C) asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other intellectual rights of others. The Company and its subsidiaries have materially complied with the terms of each agreement pursuant to which Intellectual Property has been

 

10


licensed to the Company or any subsidiary, and all such agreements are, to the Company’s knowledge, in full force and effect. To the Company’s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken reasonable steps to protect, maintain and safeguard Intellectual Property owned by the Company, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to the Company’s knowledge, no employee of the Company is in or has been in violation of any term of any such agreement. The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property owned by the Company have been materially complied with; and in all foreign offices having similar requirements, all such requirements have been materially complied with. The product candidates described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any subsidiary.

(aa) The Company and each subsidiary possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement (“Permits”), except as would not reasonably be expected to result in a Material Adverse Change, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change.

(bb) To the Company’s knowledge, the manufacturing facilities and operations of its suppliers or its subsidiaries are operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the of the U.S. Food and Drug Administration (the “FDA”) and comparable drug regulatory agencies outside of the United States to which it is subject (collectively, the “Regulatory Authorities”).

(cc) The application of the proceeds received by the Company from the issuance, sale and delivery of the Securities as described in the Pricing Disclosure Package and the Final Prospectus Supplement will not violate Regulation T, U or X of the Board of Governors of the Federal Reserve system or any other regulation of such Board of Governors.

(dd) No consent, approval, authorization, filing with or order of any court or governmental agency or body is required in connection with the transactions contemplated herein, except such as have been obtained under the Securities Act and such as may be required under the listing rules of the Nasdaq, applicable rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”) and the blue sky laws of any jurisdiction in connection with the purchase and distribution of the Securities by the Underwriters in the manner contemplated herein and in the Pricing Disclosure Package and the Final Prospectus Supplement.

 

11


(ee) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, the Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets owned by them which is material to the business of the Company, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects except as do not materially affect the value of such property and do not interfere in any material respect with the use made and currently proposed to be made of such property by the Company. The real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary.

(ff) Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, the Company and its subsidiaries (i) have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and (ii) have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them, except as may be being contested in good faith and by appropriate proceedings and for which adequate reserves are maintained in accordance with generally accepted accounting principles.

(gg) There are no transfer taxes or other similar fees or charges under federal law or the laws of any state, or any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement, any other document to be furnished hereunder or the issuance by the Company or sale by the Company of the Securities.

(hh) The Company is not, and will not be, either after receipt of payment for the Shares or after the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, required to register as an “investment company” under the Investment Company Act of 1940, as amended (the “Investment Company Act”).

(ii) The Company and each of its subsidiaries is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which it is engaged. The Company and its subsidiaries are in compliance with the terms of such policies and instruments in all material respects; and there are no material claims by the Company or any of its subsidiaries under any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights clause; neither the Company nor any such subsidiary has been refused any insurance coverage sought or applied for; and neither the Company nor any such subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not result in a Material Adverse Change.

 

12


(jj) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, no subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such subsidiary’s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s property or assets to the Company or any other subsidiary of the Company.

(kk) Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that reasonably would be expected to cause or result in stabilization or manipulation of the price of the Common Stock or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Common Stock, whether to facilitate the sale or resale of the Shares or otherwise.

(ll) There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement which have not been described as required.

(mm) All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete and correct.

(nn) Neither the Company nor any of its subsidiaries nor, to the best of the Company’s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement.

(oo) Except as described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement and except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change, (i) neither the Company nor any of its subsidiaries is in violation of any applicable federal, state, local or foreign statute, law (including fundamental principles of common law), rule, regulation or ordinance, including any judicial or administrative interpretation thereof, relating to pollution or protection of human health (to the extent relating to exposure to Hazardous Materials, defined below), the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release of pollutants, contaminants, or hazardous or toxic wastes or substances that are subject to regulation by

 

13


any governmental authority (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required of them under Environmental Laws for their operations has currently conducted and are each in compliance with the terms and conditions of such permits, authorizations and approvals, and (iii) the Company and its subsidiaries has not received written notice of any pending or threatened liability under any Environmental Law and, to the knowledge of the Company, there is no event or occurrence that would reasonably be expected to result in the receipt of any such notice.

(pp) Except as would not, individually or in the aggregate, result in a Material Adverse Change: (i) the Company and its subsidiaries and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”)) established or maintained by the Company, its subsidiaries or their “ERISA Affiliates” (as defined below) are in compliance in all material respects with ERISA; “ERISA Affiliate” means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the “Code”) of which the Company or such subsidiary is a member; (ii) no “reportable event” (as defined under ERISA), other than an event for which the 30-day notice period is waived, has occurred or is reasonably expected to occur with respect to any “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates; (iii) no “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA); (iv) neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (a) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (b) Sections 412, 4971, 4975 or 4980B of the Code; and (v) each “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would reasonably be expected to cause the loss of such qualification.

(qq) Except as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.

(rr) The Company and its subsidiaries are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change.

 

14


(ss) Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for political office; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company’s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

(tt) The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

(uu) The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement were and, if still pending, are, to the Company’s knowledge, being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company; the descriptions of the results of such studies do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading, and the Company and its subsidiaries have no knowledge of any other studies the results of which reasonably call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) except where failure to do so would not result in a Material Adverse Change; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement.

 

15


(vv) The Company: (A) is in compliance with the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.) and the regulations promulgated thereunder (the “FDCA”) except where failure to be so in compliance would not result in a Material Adverse Change; (B) has not received any FDA Form 483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from the FDA alleging or asserting material noncompliance with the FDCA or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required under the FDCA (“Authorizations”); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations except where failure to possess or be so in compliance with such Authorizations would not reasonably be expected to result in a Material Adverse Change; (D) has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any governmental entity or third party alleging that any product operation or activity is in material violation of the FDCA or the terms of any Authorization and has no knowledge that the FDA or any governmental entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, which if resolved adversely to the Company, would reasonably be expected to have a Material Adverse Change; (E) has not received written notice that the FDA or any governmental entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any governmental entity is considering such action; and (F) has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required under the FDCA or any Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission), except where instances of failure to file, obtain, maintain or submit required documentation would not reasonably be expected to result in a Material Adverse Change.

(ww) Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company, directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury of the United Kingdom, or other relevant sanctions authority (collectively, “Sanctions”); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, the Crimea region and the Donetsk People’s Republic and Luhansk People’s Republic in Ukraine, Cuba, Iran, North Korea, Syria, and

 

16


the so-called Donetsk People’s Republic and Luhansk People’s Republic regions of Ukraine (collectively, the “Sanctioned Countries”); and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.

(xx) The Company and the Company’s directors or officers, in their capacities as such, are in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder.

(yy) The Company’s and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, and databases (collectively, “IT Systems”) are reasonably adequate for the operation of the business of the Company and its subsidiaries as currently conducted. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, operation, redundancy and security of all IT Systems and data, including “Personal Data,” used in connection with their businesses. “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, or bank account information; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended; (iii) “personal data” as defined by GDPR (as defined below); (iv) any information which would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”); and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation, and together with all proprietary or confidential information of the Company, “Sensitive Data”. In the past three (3) years, there have been no breaches, violations, outages or unauthorized uses of or accesses to such Sensitive Data or IT Systems, except for those that have been remedied without material cost or liability or the duty to notify any other person under Privacy Laws (as defined below).

(zz) The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, the European Union General Data Protection Regulation (“EU GDPR”) (EU 2016/679) and the United Kingdom General Data Protection Regulation ( “UK GDPR”), and all state privacy laws (including the

 

17


California Consumer Privacy Act (“CCPA”) and similar laws in any other states) (collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps to ensure compliance in all material respects with the Company’s policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Sensitive Data (the “Policies”). The Company further certifies that neither it nor any subsidiary: (i) has received written notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action initiated by a governmental authority pursuant to any Privacy Law; or (iii) is a party to any order, decree, or settlement agreement issued by a governmental authority that imposes any obligation or liability under any Privacy Law.

(aaa) The Company (i) does not have any material lending or other relationship with any bank or lending affiliate of the Underwriters and (ii) does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to any affiliate of the Underwriters.

(bbb) The Company and its subsidiaries are, and at all times have been, in compliance with all applicable Health Care Laws, except to the extent that any non-compliance would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Public Health Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h), and applicable laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened, except in each case as would not, individually or in the

 

18


aggregate, reasonably be expected to result in a Material Adverse Change. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.

(ccc) The statements contained in the Preliminary Prospectus Supplement and the Final Prospectus Supplement under the captions “Business—Patents and Proprietary Rights,” “Business—Government Regulation,” “Risk Factors—Risks Related to Our Intellectual Property,” insofar as such statements summarize legal matters, agreements, documents, or proceedings discussed therein, are accurate and fair summaries of such legal matters, agreements, documents or proceedings.

(ddd) Any certificate signed by any officer of the Company and delivered to the Underwriters or counsel for the Underwriters in connection with the offering of the Shares shall be deemed a representation and warranty by the Company, as to matters covered thereby, to the Underwriters, as applicable.

(eee) No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in either the Pricing Disclosure Package or the Final Prospectus Supplement has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

(fff) Neither the Company nor any of its affiliates (within the meaning of FINRA Rule 5121(f)(1)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated person (within the meaning of Article I, Section 1(ee) of the bylaws of FINRA) of, any member firm of FINRA.

2. Purchase and Sale.

(a) Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth, the Company agrees to sell to each Underwriter, and each Underwriter agrees, severally and not jointly, to purchase from the Company, at the purchase price set forth in Schedule I hereto, the number of Underwritten Securities set forth opposite such Underwriter’s name in Schedule II hereto.

 

19


(b) Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth, the Company hereby grants an option to the several Underwriters to purchase, severally and not jointly, up to the number of Option Securities set forth in Schedule I hereto at the same purchase price per share as the Underwriters shall pay for the Underwritten Securities, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Securities but not payable on the Option Securities. Said option may be exercised in whole or in part at any time on or before the 30th day after the date of the Final Prospectus Supplement upon written or telegraphic notice by the Representatives to the Company setting forth the number of Option Securities as to which the several Underwriters are exercising the option and the settlement date. The number of Option Securities to be purchased by each Underwriter shall be the same percentage of the total number of Option Securities to be purchased by the several Underwriters as such Underwriter is purchasing of the Underwritten Securities, subject to such adjustments as you in your absolute discretion shall make to eliminate any fractional shares.

3. Delivery and Payment.

(a) Delivery of and payment for the Underwritten Securities and the Option Securities (if the option provided for in Section 2(b) hereof shall have been exercised on or before the first Business Day immediately preceding the Closing Date) shall be made on the date and at the time specified in Schedule I hereto or at such time on such later date not more than two Business Days after the foregoing date as the Representatives shall designate, which date and time may be postponed by agreement between the Representatives and the Company or as provided in Section 9 hereof (such date and time of delivery and payment for the Securities being herein called the “Closing Date”). As used herein, “Business Day” shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions or trust companies are authorized or obligated by law to close in New York City. Delivery of the Securities shall be made to the Representatives for the respective accounts of the several Underwriters against payment by the several Underwriters through the Representatives of the purchase price thereof to or upon the order of the Company by wire transfer payable in same-day funds to an account specified by the Company. Delivery of the Underwritten Securities (other than the Warrants) and the Option Securities shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct.

(b) If the option provided for in Section 2(b) hereof is exercised after the third Business Day immediately preceding the Closing Date, the Company will deliver the Option Securities (at the expense of the Company) to the Representatives, at 388 Greenwich Street, New York, New York, on the date specified by the Representatives (which shall be within three Business Days after exercise of said option) for the respective accounts of the several Underwriters, against payment by the several Underwriters through the Representatives of the purchase price thereof to or upon the order of the Company by wire transfer payable in same-day funds to an account specified by the Company. If settlement for the Option Securities occurs after the Closing Date, the Company will deliver to the Representatives on the settlement date for the Option Securities, and the obligation of the Underwriters to purchase the Option Securities shall be conditioned upon receipt of, supplemental opinions, certificates and letters confirming as of such date the opinions, certificates and letters delivered on the Closing Date pursuant to Section 6 hereof.

 

20


4. Offering by Underwriters. It is understood that the several Underwriters propose to offer the Securities for sale to the public as set forth in the Final Prospectus Supplement.

5. Agreements. The Company agrees with the several Underwriters that:

(a) Prior to the termination of the offering of the Securities, the Company will not file any amendment of the Registration Statement or supplement (including the Final Prospectus Supplement or any Preliminary Prospectus Supplement) to the Base Prospectus or any Rule 462(b) Registration Statement unless the Company has furnished you a copy for your review prior to filing and will not file any such proposed amendment or supplement to which you reasonably object. The Company will cause the Final Prospectus Supplement, properly completed, and any supplement thereto to be filed in a form approved by the Representatives with the SEC pursuant to the applicable paragraph of Rule 424(b) within the time period prescribed and will provide evidence satisfactory to the Representatives of such timely filing. The Company will promptly advise the Representatives (i) when the Final Prospectus Supplement, and any supplement thereto, shall have been filed (if required) with the SEC pursuant to Rule 424(b) or when any Rule 462(b) Registration Statement shall have been filed with the SEC, (ii) when, prior to termination of the offering of the Securities, any amendment to the Registration Statement shall have been filed or become effective, (iii) of any request by the SEC or its staff for any amendment of the Registration Statement, or any Rule 462(b) Registration Statement, or for any supplement to the Final Prospectus Supplement or for any additional information, (iv) of the issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement or of any notice objecting to its use or the institution or threatening of any proceeding for that purpose and (v) of the receipt by the Company of any notification with respect to the suspension of the qualification of the Securities for sale in any jurisdiction or the institution or threatening of any proceeding for such purpose. The Company will use its best efforts to prevent the issuance of any such stop order or the occurrence of any such suspension or objection to the use of the Registration Statement and, upon such issuance, occurrence or notice of objection, to obtain as soon as possible the withdrawal of such stop order or relief from such occurrence or objection, including, if necessary, by filing an amendment to the Registration Statement or a new registration statement and using its best efforts to have such amendment or new registration statement declared effective as soon as practicable.

(b) If, at any time prior to the filing of the Final Prospectus Supplement pursuant to Rule 424(b), any event occurs as a result of which the Pricing Disclosure Package would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading, the Company will (i) notify promptly the Representatives so that any use of the Pricing Disclosure Package may cease until it is amended or supplemented; (ii) amend or supplement the Pricing Disclosure Package to correct such statement or omission; and (iii) supply any amendment or supplement to you in such quantities as you may reasonably request.

 

21


(c) If, at any time when a prospectus relating to the Securities is required to be delivered under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172), any event occurs as a result of which the Final Prospectus Supplement as then supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein in the light of the circumstances under which they were made or the circumstances then prevailing not misleading, or if it shall be necessary to amend the Registration Statement, file a new registration statement or supplement the Final Prospectus Supplement to comply with the Securities Act or the Exchange Act or the respective rules thereunder, including in connection with use or delivery of the Final Prospectus Supplement, the Company promptly will (i) notify the Representatives of any such event, (ii) prepare and file with the SEC, subject to the second sentence of paragraph (a) of this Section 5, an amendment or supplement or new registration statement which will correct such statement or omission or effect such compliance, (iii) use its best efforts to have any amendment to the Registration Statement or new registration statement declared effective as soon as practicable in order to avoid any disruption in use of the Final Prospectus Supplement and (iv) supply any supplemented Final Prospectus Supplement to you in such quantities as you may reasonably request.

(d) As soon as practicable, the Company will make generally available to its security holders and to the Representatives an earnings statement or statements of the Company and its subsidiaries which will satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act.

(e) The Company will furnish to the Representatives and counsel for the Underwriters, without charge, signed copies of the Registration Statement (including exhibits thereto) and to each other Underwriter a copy of the Registration Statement (without exhibits thereto) and, so long as delivery of a prospectus by an Underwriter or dealer may be required by the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172), as many copies of each Preliminary Prospectus Supplement, the Final Prospectus Supplement and each Issuer Free Writing Prospectus and any supplement thereto as the Representatives may reasonably request. The Company will pay the expenses of printing or other production of all documents relating to the offering.

(f) The Company will arrange, if necessary, for the qualification of the Securities for sale under the laws of such jurisdictions as the Representatives may designate and will maintain such qualifications in effect so long as required for the distribution of the Securities; provided that in no event shall the Company be obligated to qualify to do business in any jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits, other than those arising out of the offering or sale of the Securities, in any jurisdiction where it is not now so subject.

 

22


(g) The Company will not, without the prior written consent of the Citigroup Global Markets Inc., offer, sell, contract to sell, pledge, hedge, or otherwise dispose of, (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the Company or any affiliate of the Company or any person in privity with the Company or any affiliate of the Company) directly or indirectly, including the submission or filing (or participation in the submission or filing) of a registration statement with the SEC in respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act, any other shares of Common Stock or any securities convertible into, or exercisable, or exchangeable for, shares of Common Stock; or publicly announce an intention to effect any such transaction, for a period of 60 days after the date of this Agreement (such period, the “Company Lock-up Period”), provided, however, that the Company may: (i) effect the transactions contemplated hereby and issue shares of Common Stock pursuant to the potential concurrent private placement described in the Registration Statement, the Pricing Disclosure Package and the Final Prospectus Supplement; (ii) issue warrants to purchase shares of Common Stock with a value equal to $437,500, as required in the event that the Company elects to obtain a Term B Loan within 30 days upon the FDA’s acceptance of the Company’s NDA for sotagliflozin pursuant to the Company’s Loan and Security Agreement, dated March 17, 2022, with Oxford Finance, LLC, provided that if any filing under Section 16(a) of the Exchange Act shall be legally required during the Company Lock-Up Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; (iii) grant options, restricted stock units or other equity awards or issue shares of Common Stock to its employees, officers, directors, advisors or consultants pursuant to employee benefit plans of the Company, provided, that each recipient of such securities that is a newly appointed director or executive officer pursuant to this clause (iii) agree to restrictions on the resale of securities that are consistent with the provisions set forth in the lock-up letter described in Section 6(l) hereof; and (iv) file one or more registration statements on Form S-8 relating to stock options or employee benefit plans of the Company, and provided, further, that each recipient of such securities that is a newly appointed director or executive officer agrees to restrictions on the resale of securities that are consistent with the provisions set forth in the lock-up letter described in Section 6(l) hereof. The Company will provide the Representatives and each individual subject to the restricted period pursuant to the lock-up letters described in Section 6(l) hereof with prior notice of any such announcement that gives rise to an extension of the restricted period.

(h) The Company will use its reasonable best efforts to maintain the listing of the Shares issued and sold by the Company on The Nasdaq Global Select Market.

(i) The Company will not take, directly or indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.

 

23


(j) The Company agrees to pay the costs and expenses relating to the following matters: (i) the preparation, printing or reproduction and filing with the SEC of the Registration Statement (including financial statements and exhibits thereto), each Preliminary Prospectus Supplement, the Final Prospectus Supplement and each Issuer Free Writing Prospectus, and each amendment or supplement to any of them; (ii) the printing (or reproduction) and delivery (including postage, air freight charges and charges for counting and packaging) of such copies of the Registration Statement, each Preliminary Prospectus Supplement, the Final Prospectus Supplement and each Issuer Free Writing Prospectus, and all amendments or supplements to any of them, as may, in each case, be reasonably requested for use in connection with the offering and sale of the Securities; (iii) the preparation, printing, authentication, issuance and delivery of certificates for the Securities, including any stamp or transfer taxes in connection with the original issuance and sale of the Securities; (iv) the printing (or reproduction) and delivery of this Agreement, any blue sky memorandum and all other agreements or documents printed (or reproduced) and delivered in connection with the offering of the Securities; (v) the registration of the Securities under the Exchange Act and the listing of the Securities on Nasdaq; (vi) any registration or qualification of the Securities for offer and sale under the securities or blue sky laws of the several states (including filing fees and the reasonable fees and expenses of counsel for the Underwriters relating to such registration and qualification); (vii) FINRA (including filing fees and the reasonable fees and expenses of counsel for the Underwriters relating to such filings); (viii) the transportation and other expenses incurred by or on behalf of Company representatives in connection with presentations to prospective purchasers of the Securities; (ix) the fees and expenses of the Company’s accountants and the fees and expenses of counsel (including local and special counsel) for the Company; and (x) all other costs and expenses incident to the performance by the Company of its obligations hereunder, provided, however, that the reasonable fees and expenses of counsel for the Underwriters incurred pursuant to clauses (vi) and (vii) of this Section 5(j) shall not exceed $20,000 in the aggregate.

(k) The Company agrees that, unless it has or shall have obtained the prior written consent of the Representatives, and each Underwriter, severally and not jointly, agrees with the Company that, unless it has or shall have obtained, as the case may be, the prior written consent of the Company, it has not made and will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a Free Writing Prospectus required to be filed by the Company with the SEC or retained by the Company under Rule 433 under the Securities Act (“Rule 433”); provided that the prior written consent of the parties hereto shall be deemed to have been given in respect of the Free Writing Prospectuses included in Schedule III hereto and any electronic road show. The Company agrees that (x) it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and (y) it has complied and will comply, as the case may be, with the requirements of Rule 164 under the Securities Act (“Rule 164”) and Rule 433 applicable to any Permitted Free Writing Prospectus, including in respect of timely filing with the SEC, legending and record keeping.

 

24


6. Conditions to the Obligations of the Underwriters. The obligations of the Underwriters to purchase the Underwritten Securities and the Option Securities, as the case may be, shall be subject to the accuracy of the representations and warranties on the part of the Company contained herein as of the Execution Time, the Closing Date and any settlement date pursuant to Section 3 hereof, to the accuracy of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder and to the following additional conditions:

(a) The Final Prospectus Supplement, and any supplement thereto, have been filed in the manner and within the time period required by Rule 424(b); any material required to be filed by the Company pursuant to Rule 433(d) shall have been filed with the SEC within the applicable time periods prescribed for such filings by Rule 433; and no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use shall have been issued and no proceedings for that purpose shall have been instituted or threatened.

(b) The Company shall have requested and caused Brian T. Crum, Senior Vice President and General Counsel of the Company, to have furnished to the Representatives an opinion, dated the Closing Date and addressed to the Representatives, in form and substance satisfactory to the Representatives.

(c) The Company shall have requested and caused Max Bachrach, Ph.D., Vice President, Intellectual Property, of the Company, to have furnished to the Representatives an opinion with respect to intellectual property matters, dated the Closing Date and addressed to the Representatives, in form and substance satisfactory to the Representatives.

(d) The Company shall have requested and caused Vinson & Elkins LLP, counsel for the Company, to have furnished to the Representatives their opinion and negative assurance letter, dated the Closing Date and addressed to the Representatives, in form and substance satisfactory to the Representatives.

(e) The Representatives shall have received from Cooley LLP, counsel for the Underwriters, such opinion or opinions and negative assurance letter, dated the Closing Date and addressed to the Representatives, with respect to the issuance and sale of the Securities, the Registration Statement, the Pricing Disclosure Package, the Final Prospectus Supplement (together with any supplement thereto) and other related matters as the Representatives may reasonably require, and the Company shall have furnished to such counsel such documents as they request for the purpose of enabling them to pass upon such matters.

(f) The Company shall have furnished to the Representatives a certificate of the Company, signed by the Chief Executive Officer or other principal executive officer of the Company, dated the Closing Date, to the effect that the signers of such certificate have carefully examined the Registration Statement, the Pricing Disclosure Package, the Final Prospectus Supplement and any amendments or supplements thereto, as well as each electronic road show used in connection with the offering of the Securities, and this Agreement and that:

(i) the representations and warranties of the Company in this Agreement are true and correct on and as of the Closing Date with the same effect as if made on the Closing Date and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the Closing Date;

 

25


(ii) no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use has been issued and no proceedings for that purpose have been instituted or, to the Company’s knowledge, threatened; and

(iii) since the date of the most recent financial statements included or incorporated by reference in the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto), there has been no Material Adverse Change in the condition (financial or otherwise), prospects, earnings, business or properties of the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto).

(g) The Company shall have requested and caused Ernst & Young LLP to have furnished to the Representatives, at the Execution Time and at the Closing Date, letters (which may refer to letters previously delivered to one or more of the Representatives), dated respectively as of the Execution Time and as of the Closing Date, in form and substance satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountants “comfort letters” to underwriters.

(h) Subsequent to the Execution Time or, if earlier, the dates as of which information is given in the Registration Statement (exclusive of any amendment thereof) and the Final Prospectus Supplement (exclusive of any supplement thereto), there shall not have been (i) any change or decrease specified in the letter or letters referred to in paragraph (e) of this Section 6 or (ii) any change, or any development involving a prospective change, in or affecting the condition (financial or otherwise), earnings, business or properties of the Company and its subsidiaries taken as a whole, whether or not arising from transactions in the ordinary course of business, except as set forth in or contemplated in the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto) the effect of which, in any case referred to in clause (i) or (ii) above, is, in the sole judgment of the Representatives, so material and adverse as to make it impractical or inadvisable to proceed with the offering or delivery of the Securities as contemplated by the Registration Statement (exclusive of any amendment thereof), the Pricing Disclosure Package and the Final Prospectus Supplement (exclusive of any amendment or supplement thereto).

 

26


(i) Prior to the Closing Date, the Company shall have furnished to the Representatives such further information, certificates and documents as the Representatives may reasonably request.

(j) Subsequent to the Execution Time, there shall not have been any decrease in the rating of any of the Company’s debt securities by any “nationally recognized statistical rating organization” (as defined for purposes of Rule 3(a)(62) under the Exchange Act) or any notice given of any intended or potential decrease in any such rating or of a possible change in any such rating that does not indicate the direction of the possible change.

(k) The Securities shall have been listed and admitted and authorized for trading on Nasdaq, and satisfactory evidence of such actions shall have been provided to the Representatives.

(l) At the Execution Time, the Company shall have furnished to the Representatives a lock-up letter substantially in the form of Exhibit A hereto from each executive officer and director of the Company and certain stockholders of the Company addressed to the Representatives.

If any of the conditions specified in this Section 6 shall not have been fulfilled when and as provided in this Agreement, or if any of the opinions and certificates mentioned above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Representatives and counsel for the Underwriters, this Agreement and all obligations of the Underwriters hereunder may be canceled at, or at any time prior to, the Closing Date by the Representatives. Notice of such cancellation shall be given to the Company in writing or by telephone or facsimile confirmed in writing.

The documents required to be delivered by this Section 6 shall be delivered electronically to Cooley LLP, counsel for the Underwriters, on the Closing Date.

7. Reimbursement of Underwriters’ Expenses. If the sale of the Securities provided for herein is not consummated because any condition to the obligations of the Underwriters set forth in Section 6 hereof is not satisfied, because of any termination pursuant to Section 10 hereof or because of any refusal, inability or failure on the part of the Company to perform any agreement herein or comply with any provision hereof other than by reason of a default by any of the Underwriters, the Company will reimburse the Underwriters severally through Citigroup Global Markets Inc. on demand for all expenses (including reasonable fees and disbursements of counsel) that shall have been incurred by them in connection with the proposed purchase and sale of the Securities.

8. Indemnification and Contribution.

(a) The Company agrees to indemnify and hold harmless each Underwriter, the directors, officers, employees, affiliates and agents of each Underwriter and each person who controls any Underwriter within the meaning of either the Securities Act or the Exchange Act against any and all losses, claims, damages or liabilities, joint or several, to which they or any of them may become subject under the Securities Act, the

 

27


Exchange Act or other Federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in the registration statement for the registration of the Securities as originally filed or in any amendment thereof, or in the Base Prospectus, any Preliminary Prospectus Supplement or any other preliminary prospectus supplement relating to the Securities, the Final Prospectus Supplement, or any Issuer Free Writing Prospectus or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and agrees to reimburse each such indemnified party, as incurred, for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Company by or on behalf of any Underwriter through the Representatives specifically for inclusion therein. This indemnity agreement will be in addition to any liability which the Company may otherwise have.

(b) Each Underwriter severally and not jointly agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signs the Registration Statement, and each person who controls the Company within the meaning of either the Securities Act or the Exchange Act, to the same extent as the foregoing indemnity from the Company to each Underwriter, but only with reference to written information relating to such Underwriter furnished to the Company by or on behalf of such Underwriter through the Representatives specifically for inclusion in the documents referred to in the foregoing indemnity. This indemnity agreement will be in addition to any liability which any Underwriter may otherwise have. The Company acknowledges that the statements set forth (i) in the last paragraph of the cover page regarding delivery of the Securities and, under the heading “Underwriting” (ii) the list of Underwriters and their respective participation in the sale of the Securities, (iii) the sentences related to concessions and reallowances and (iv) the paragraph related to stabilization, syndicate covering transactions and penalty bids in any Preliminary Prospectus Supplement and the Final Prospectus Supplement constitute the only information furnished in writing by or on behalf of the several Underwriters for inclusion in any Preliminary Prospectus Supplement, the Final Prospectus Supplement or any Issuer Free Writing Prospectus.

(c) Promptly after receipt by an indemnified party under this Section 8 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section 8, notify the indemnifying party in writing of the commencement thereof; but the failure so to notify the indemnifying party (i) will not relieve it from liability under paragraph (a) or (b) above unless and to the extent it did not otherwise learn of such action and such failure results in the forfeiture by the indemnifying party of substantial rights and defenses and (ii) will not, in any event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided

 

28


in paragraph (a) or (b) above. The indemnifying party shall be entitled to appoint counsel of the indemnifying party’s choice at the indemnifying party’s expense to represent the indemnified party in any action for which indemnification is sought (in which case the indemnifying party shall not thereafter be responsible for the fees and expenses of any separate counsel retained by the indemnified party or parties except as set forth below); provided, however, that such counsel shall be satisfactory to the indemnified party. Notwithstanding the indemnifying party’s election to appoint counsel to represent the indemnified party in an action, the indemnified party shall have the right to employ separate counsel (including local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel if (i) the use of counsel chosen by the indemnifying party to represent the indemnified party would present such counsel with a conflict of interest, (ii) the actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, (iii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of the institution of such action or (iv) the indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party. An indemnifying party will not, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such claim, action, suit or proceeding and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party.

(d) In the event that the indemnity provided in paragraph (a), (b) or (c) of this Section 8 is unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company and the Underwriters severally agree to contribute to the aggregate losses, claims, damages and liabilities (including legal or other expenses reasonably incurred in connection with investigating or defending the same) (collectively, “Losses”) to which the Company and one or more of the Underwriters may be subject in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and by the Underwriters on the other from the offering of the Securities. If the allocation provided by the immediately preceding sentence is unavailable for any reason, the Company and the Underwriters severally shall contribute in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and of the Underwriters on the other in connection with the statements or omissions which resulted in such Losses as well as any other relevant equitable considerations. Benefits received by the Company shall be deemed to be equal to the total net proceeds from the offering (before deducting expenses) received by it, and benefits received by the Underwriters shall be deemed to be equal to the total underwriting discounts and commissions, in each case as set forth on the cover page of the Final Prospectus Supplement. Relative fault shall be determined by reference to,

 

29


among other things, whether any untrue or any alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information provided by the Company on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contribution were determined by pro rata allocation or any other method of allocation which does not take account of the equitable considerations referred to above. Notwithstanding the provisions of this paragraph (d), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. Notwithstanding the provisions of this paragraph (d), no person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 8, each person who controls an Underwriter within the meaning of either the Securities Act or the Exchange Act and each director, officer, employee, affiliate and agent of an Underwriter shall have the same rights to contribution as such Underwriter, and each person who controls the Company within the meaning of either the Securities Act or the Exchange Act, each officer of the Company who shall have signed the Registration Statement and each director of the Company shall have the same rights to contribution as the Company, subject in each case to the applicable terms and conditions of this paragraph (d).

9. Default by an Underwriter. If any one or more Underwriters shall fail to purchase and pay for any of the Securities agreed to be purchased by such Underwriter or Underwriters hereunder and such failure to purchase shall constitute a default in the performance of its or their obligations under this Agreement, the remaining Underwriters shall be obligated severally to take up and pay for (in the respective proportions which the amount of Securities set forth opposite their names in Schedule II hereto bears to the aggregate amount of Securities set forth opposite the names of all the remaining Underwriters) the Securities which the defaulting Underwriter or Underwriters agreed but failed to purchase; provided, however, that in the event that the aggregate amount of Securities which the defaulting Underwriter or Underwriters agreed but failed to purchase shall exceed 10% of the aggregate amount of Securities set forth in Schedule II hereto, the remaining Underwriters shall have the right to purchase all, but shall not be under any obligation to purchase any, of the Securities, and if such non-defaulting Underwriters do not purchase all the Securities, this Agreement will terminate without liability to any non-defaulting Underwriter or the Company. In the event of a default by any Underwriter as set forth in this Section 9, the Closing Date shall be postponed for such period, not exceeding five Business Days, as the Representatives shall determine in order that the required changes in the Registration Statement and the Final Prospectus Supplement or in any other documents or arrangements may be effected. Nothing contained in this Agreement shall relieve any defaulting Underwriter of its liability, if any, to the Company and any non-defaulting Underwriter for damages occasioned by its default hereunder.

 

30


10. Termination. This Agreement shall be subject to termination in the absolute discretion of the Representatives, by notice given to the Company prior to delivery of and payment for the Securities, if at any time prior to such delivery and payment (i) trading in the Company’s Common Stock shall have been suspended by the SEC or Nasdaq or trading in securities generally on the New York Stock Exchange or Nasdaq shall have been suspended or limited or minimum prices shall have been established on either of such exchanges, (ii) a banking moratorium shall have been declared either by Federal or New York State authorities, (iii) there shall have occurred a material disruption in commercial banking or securities settlement or clearance services or (iv) there shall have occurred any outbreak or escalation of hostilities, declaration by the United States of a national emergency or war, or other calamity or crisis the effect of which on financial markets is such as to make it, in the sole judgment of the Representatives, impractical or inadvisable to proceed with the offering or delivery of the Securities as contemplated by any Preliminary Prospectus Supplement or the Final Prospectus Supplement (exclusive of any amendment or supplement thereto).

11. Representations and Indemnities to Survive. The respective agreements, representations, warranties, indemnities and other statements of the Company or its officers and of the Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of the officers, directors, employees, agents, affiliates or controlling persons referred to in Section 8 hereof, and will survive delivery of and payment for the Securities. The provisions of Sections 7 and 8 hereof shall survive the termination or cancellation of this Agreement.

12. Notices. All communications hereunder will be in writing and effective only on receipt, and, if sent to the Representatives, will be mailed, delivered, telefaxed to c/o Citigroup Global Markets Inc. at 388 Greenwich Street, New York, New York 10013, Attention: General Counsel, facsimile number: +1 (646) 291-1469 and Piper Sandler & Co., 800 Nicollet Mall, Minneapolis, Minnesota 55402, attention: General Counsel, LegalCapMarkets@psc.com; or, if sent to Lexicon Pharmaceuticals, Inc., will be mailed, delivered or telefaxed to 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381, Attention: General Counsel.

13. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers, directors, employees, agents and controlling persons referred to in Section 8 hereof, and no other person will have any right or obligation hereunder.

14. Jurisdiction. The Company agrees that any suit, action or proceeding against the Company brought by any Underwriter, the directors, officers, employees, affiliates and agents of any Underwriter, or by any person who controls any Underwriter, arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in any State or U.S. federal court in The City of New York and County of New York, and waives any objection which it may now or hereafter have to the laying of venue of any such proceeding, and irrevocably submits to the non-exclusive jurisdiction of such courts in any suit, action or proceeding.

 

31


15. Recognition of the U.S. Special Resolution Regimes.

(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

As used in this Section 15, “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k); “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b), (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b) or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

16. No Fiduciary Duty. The Company hereby acknowledges that (a) the purchase and sale of the Securities pursuant to this Agreement is an arm’s-length commercial transaction between the Company, on the one hand, and the Underwriters and any affiliate through which it may be acting, on the other, (b) the Underwriters are acting as principal and not as an agent or fiduciary of the Company and (c) the Company’s engagement of the Underwriters in connection with the offering and the process leading up to the offering is as independent contractors and not in any other capacity. Furthermore, the Company agrees that it is solely responsible for making its own judgments in connection with the offering (irrespective of whether any of the Underwriters has advised or is currently advising the Company on related or other matters). The Company agrees that it will not claim that the Underwriters have rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto.

17. Integration. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof.

 

32


18. Applicable Law. This Agreement will be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed within the State of New York.

19. Waiver of Jury Trial. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

20. Counterparts. This Agreement may be signed in one or more counterparts, each of which shall constitute an original and all of which together shall constitute one and the same agreement. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

21. Headings. The section headings used herein are for convenience only and shall not affect the construction hereof.

 

33


If the foregoing is in accordance with your understanding of our agreement, please sign and return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall represent a binding agreement among the Company and the several Underwriters.

 

Very truly yours,
LEXICON PHARMACEUTICALS, INC.
By:   /s/ Jeffrey L. Wade
Name:   Jeffrey L. Wade
Title:   President and Chief Financial Officer

[Signature Page to Underwriting Agreement]


The foregoing Agreement is hereby

confirmed and accepted as of the date

specified in Schedule I hereto.

 

CITIGROUP GLOBAL MARKETS INC.

PIPER SANDLER & CO.

CITIGROUP GLOBAL MARKETS INC.

By:

  /s/ Michael Brock

Name:

  Michael Brock

Title:

  Managing Director

PIPER SANDLER & CO.

By:

  /s/ Neil Riley

Name:

  Neil Riley

Title:

  Managing Director

For themselves and the other several

Underwriters named in Schedule II to

the foregoing Agreement.

[Signature Page to Underwriting Agreement]


SCHEDULE I

Underwriting Agreement, dated July 27, 2022

Registration Statement No. 333-258564

Representatives: Citigroup Global Markets Inc. and Piper Sandler & Co.

Title, Purchase Price and Description of Securities:

Title: Common Stock, par value $0.001

Number of Underwritten Securities to be sold by the Company: 16,843,600

Number of Option Securities to be sold by the Company: 2,526,540

Price per Share to Public (include accrued dividends, if any): $2.50

Price per Share to the Underwriters – total: $2.35

Other provisions: None.

Closing Date, Time and Location: August 1, 2022 at 10:00 a.m., New York City time, at Cooley LLP, 55 Hudson Yards, New York, New York 10001

Type of Offering: Non-Delayed

 

I-1


SCHEDULE II

 

Underwriters

   Number of Underwritten
Securities to be Purchased
 

Citigroup Global Markets Inc.

     9,685,070  

Piper Sandler & Co.

     7,158,530  

Total

     16,843,600  
  

 

 

 

 

II-1


SCHEDULE III

Schedule of Free Writing Prospectuses included in the Pricing Disclosure Package

None.

 

III-1


EXHIBIT A

Form of Lock-up Agreement

LOCK-UP AGREEMENT

___________________, 2022

Citigroup Global Markets Inc.

Piper Sandler & Co.

As Representatives of the several Underwriters

 

c/o

Citigroup Global Markets Inc.

388 Greenwich Street

New York, New York 10013

 

c/o

Piper Sandler & Co.

800 Nicollet Mall

Minneapolis, Minnesota 55402

Ladies and Gentlemen:

The undersigned understands that Citigroup Global Markets Inc. (“Citigroup”) and Piper Sandler & Co. (together with Citigroup, the “Representatives”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Offering”) by the several Underwriters listed in Schedule II to the Underwriting Agreement (the “Underwriters”) of shares (the “Shares”) of the common stock, par value $0.001 per share, of the Company (the “Common Stock”).

To induce the Underwriters that may participate in the Offering to continue their efforts in furtherance thereof, the undersigned hereby agrees not to, during the period commencing on the date hereof and ending 60 days after the date of the final prospectus supplement relating to the Offering (the “Prospectus”) (“such period, the “Lock-Up Period”), without the prior written consent of Citigroup on behalf of the Underwriters, (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), by the undersigned or any other securities so owned convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (a) transactions relating to shares of Common Stock or other securities acquired in open market transactions after the completion of the Offering, provided that no filing under Section 16(a) of the Exchange Act shall be required or shall be voluntarily made in connection with subsequent sales of Common Stock or other securities acquired in such open market transactions, (b) any surrender of shares of Common Stock (or options to purchase shares of Common Stock) to the Company by the undersigned in

 

A-1


satisfaction of (i) any federal, state or local taxes required by law to be withheld with respect to the vesting of shares of Common Stock or the exercise of stock options to purchase Common Stock and/or (ii) the exercise price payable to the Company with respect to the exercise of stock options to purchase Common Stock, in each case granted under a stock incentive plan or stock purchase plan of the Company described in the Prospectus or any document incorporated by reference therein and in accordance with the terms of any such instrument as in effect on or before the date hereof, (c) transfers of shares of Common Stock or any security convertible into Common Stock as a bona fide gift, (d) distributions of shares of Common Stock or any security convertible into Common Stock to limited partners, members, stockholders or equityholders of the undersigned, (e) transfers to immediate family of the undersigned, to a trust all of the beneficiaries of which are the undersigned and/or members of his or her immediate family or to a corporation, partnership, limited partnership or limited liability company all of the stockholders, partners and members of which are the undersigned and/or members of his or her immediate family, in each case for estate planning purposes, (f) transfers by will or other testamentary document, or intestacy; provided that (i) in the case of any transfer or distribution pursuant to clauses (c) – (f) each donee or distributee shall sign and deliver a lock-up agreement substantially in the form of this agreement and (ii) in the case of any surrender, transfer or distribution pursuant to clauses (b) – (f), no filing under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the Lock-Up Period, (g) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Common Stock; provided that such plan does not provide for the transfer of Common Stock during the Lock-Up Period, except as otherwise permitted herein, and no public announcement or filing under the Exchange Act regarding the establishment of such plan shall be required of or voluntarily made by or on behalf of the undersigned or the Company during the Lock-Up Period or (h) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement; provided that if any filing under Section 16(a) of the Exchange Act shall be legally required during the Lock-Up Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer. For purposes of this agreement, “immediate family” shall mean spouse, lineal descendant, father, mother, brother or sister of the transferor.

In addition, the undersigned agrees that, without the prior written consent of Citigroup on behalf of the Underwriters, it will not, during the period commencing on the date hereof and ending 60 days after the date of the Prospectus, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s shares of Common Stock except in compliance with the foregoing restrictions.

The undersigned acknowledges and agrees that none of the Underwriters has made any recommendation or provided any investment or other advice to the undersigned with respect to this agreement or the subject matter hereof, and the undersigned has consulted its own legal, accounting, financial, regulatory, tax and other advisors with respect to this agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may provide certain Regulation Best Interest and Form CRS disclosures or other related documentation to you in connection with the Offering, the Underwriters are not making a recommendation to you to participate in the Offering or sell any shares at the price determined in the Offering, and nothing set forth in such disclosures or documentation is intended to suggest that any Underwriter is making such a recommendation.

 

A-2


This agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

This agreement shall automatically terminate, and the undersigned shall be automatically released from its obligations hereunder, upon the earliest to occur, if any, of (1) the execution of the Underwriting Agreement in connection with the Offering shall not have occurred on or before August 31, 2022, (2) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder or (3) the Representatives, on behalf of the Underwriters, advise the Company, or the Company advises the Representatives, in writing, prior to the execution of the Underwriting Agreement, that they have determined not to proceed with the Offering.

The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this agreement. This agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.

This agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

 

A-3


Very truly yours,
 
Name of Securityholder (Print exact name)
By:    
  Signature
If not signing in an individual capacity:
 
Name of Authorized Signatory (Print)
 
Title of Authorized Signatory (Print)
(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)
EX-5.1 3 d342123dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

LOGO

July 28, 2022

Lexicon Pharmaceuticals, Inc.

800 Technology Forest Place

The Woodlands, TX 77381

Ladies and Gentlemen:

We have acted as counsel for Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), with respect to certain legal matters in connection with the proposed issuance and sale by the Company of 19,370,140 shares (the “Shares”) of common stock, par value $0.001 (the “Common Stock”). The Shares are being offered, issued and sold pursuant to an Underwriting Agreement dated July 27, 2022 by and among the Company, and Citigroup Global Markets Inc. and Piper Sandler & Co., as representatives for the several underwriters named in Schedule II thereto (the “Underwriting Agreement”).

We have participated in the preparation of a Prospectus Supplement dated July 27, 2022 (the “Prospectus Supplement”), forming part of the Registration Statement on Form S-3, effective as of September 14, 2021 (the “Registration Statement”), that also contains a base prospectus (the “Base Prospectus” and, together with the Prospectus Supplement, the “Prospectus”). The Prospectus Supplement has been filed pursuant to Rule 424(b) promulgated under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (the “Securities Act”).

In rendering the opinions set forth below, we have examined and relied upon (i) the Registration Statement and the Prospectus; (ii) the Fifth Amended and Restated Certificate of Incorporation of the Company, as amended to the date hereof; (iii) the Second Amended and Restated Bylaws of the Company, as amended to the date hereof; (iv) the Underwriting Agreement; (v) resolutions of the Board of Directors of the Company dated July 22, 2022 and resolutions of the Pricing Committee of the Board of Directors of the Company dated July 27, 2022; and (vi) such other certificates and other instruments and documents as we consider appropriate for purposes of the opinions hereafter expressed.

In connection with this opinion, we have assumed that all Shares will be issued and sold in the manner stated in the Prospectus and the Underwriting Agreement.

Based upon the foregoing and subject to the assumptions, exceptions, limitations and qualifications set forth below, we are of the opinion that the Shares, when issued and delivered against payment therefor in accordance with the Underwriting Agreement, will be validly issued, fully paid and non-assessable, except as described in the Registration Statement and the Prospectus.

 

Vinson & Elkins LLP Attorneys at Law

Austin Dallas Dubai Houston London Los Angeles New York

Richmond Riyadh San Francisco Tokyo Washington

  

845 Texas Avenue, Suite 4700

Houston, TX 77002

Tel +1.713.758.2222 Fax +1.713.758.2346 velaw.com


LOGO    July 28, 2022 Page 2

The opinions expressed herein are qualified in the following respects:

A. We have assumed that (i) each document submitted to us for review is accurate and complete, each such document that is an original is authentic, each such document that is a copy conforms to an authentic original and all signatures on each such document are genuine, and (ii) each certificate from governmental officials reviewed by us is accurate, complete and authentic, and all official public records are accurate and complete.

B. This opinion is limited in all respects to the federal laws of the United States, the Delaware General Corporation Law and the Constitution of the State of Delaware, as interpreted by the courts of the State of Delaware and of the United States. We are expressing no opinion as to the effect of the laws of any other jurisdiction.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Company’s Current Report on Form 8-K dated on or about the date hereof, to the incorporation by reference of this opinion into the Registration Statement and to the reference to our firm under the caption “Legal Matters” in the Prospectus forming a part of the Registration Statement. In giving this consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange Commission thereunder.

 

Very truly yours,
/s/ Vinson & Elkins L.L.P.
Vinson & Elkins L.L.P.
EX-10.1 4 d342123dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

EXECUTION VERSION

PURCHASE AGREEMENT

July 27, 2022

Artal International S.C.A.

44 rue de la Vallée

L-2661 Luxembourg

Luxembourg

Attention: Anne Goffard

The Invus Group, L.L.C.

750 Lexington Avenue (30th Floor)

New York, New York 10022

Attention: David van Zandt

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Blvd., 11th Floor

The Woodlands, Texas 77381

Attn: President and Chief Executive Officer

Ladies and Gentlemen:

Reference is made to (a) that certain Underwriting Agreement being entered into by Lexicon Pharmaceuticals, Inc. (the “Company”) with the representatives of the underwriters named in Schedule II thereto (the “Underwriters”) concurrently with this Agreement (the “Underwriting Agreement”) providing for the issuance by the Company to the Underwriters (the “Public Offering”) of 16,843,600 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), plus up to 2,526,540 additional shares of Common Stock (the “Option Shares”) that may be issued pursuant to the Underwriters’ option to purchase additional shares of Common Stock provided for in Section 2(b) of the Underwriting Agreement (the “Option”), for sale in a public offering at a price to the public of $2.50 per share (the “Purchase Price”), (b) the Fifth Amended and Restated Certificate of Incorporation of the Company, dated May 20, 2022 (the “Certificate of Incorporation”) and (c) the Registration Rights Agreement, dated as of June 17, 2007 (as amended, supplemented or otherwise modified, the “Registration Rights Agreement”), by and between Invus, L.P. and the Company. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Underwriting Agreement.

In consideration of the mutual covenants and agreements herein contained, and intending to be legally bound hereby, pursuant to Section 12.01(c) of the Certificate of Incorporation and Section 2.02(a) of the Registration Rights Agreement, each of Artal International S.C.A. (the “Investor”), Artal Group S.A., Artal International Management S.A., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Mr. Amaury Wittouck, Stichting Administratiekantoor Westend and Westend S.A. (the “Invus Entities”), as applicable, hereby waives its rights under (A) Section 12.01 of the Certificate of Incorporation to purchase the Firm Shares and Option Shares in connection with the Public Offering and (B) Section 2.02 of the Registration Rights Agreement the opportunity to include in the Public Offering its Registrable Securities (as defined in the Registration Rights Agreement), and the Investor shall purchase, subject to the terms and conditions herein, (i) 16,173,800 shares of Common Stock (the “Firm Investor Shares”) and (ii) in the event that the Underwriters exercise the Option, up to 2,426,070 shares of Common Stock (the “Option Investor Shares”).

 

I.

The Firm Investor Shares

Subject to the satisfaction or waiver of the conditions described in Section V, the Investor hereby agrees to purchase the Firm Investor Shares from the Company at the Purchase Price. The total purchase price for the Firm Investor Shares shall be equal to $40,434,500.

The closing of the sale of the Firm Investor Shares shall take place concurrently with the closing of the sale of the Firm Shares under the Underwriting Agreement (the “Firm Closing Date”), (i) with payment for the Firm Investor Shares to be made to the Company by wire transfer of immediately available funds on the Firm Closing Date and (ii) with delivery of the Firm Investor Shares registered, as applicable, in the name of the Investor or its designees and otherwise free and clear of all liens, with any transfer or stamp taxes duly paid by the Company.


II.

The Option Investor Shares

In the event that the Underwriters exercise the Option, the Investor shall have the option to purchase, at the Purchase Price, a number of Option Investor Shares from the Company, determined by multiplying 2,426,070 by a fraction, the numerator of which shall be the number of Option Shares as to which the Underwriters exercise the Option and the denominator of which shall be the maximum number of Option Shares subject to the Option, rounded down to the nearest whole number.

The closing of the sale of the Option Investor Shares purchased pursuant to this Section II shall take place concurrently with the closing of the sale of the Option Shares, as to which the Underwriters exercise the Option (the “Option Closing Date”), (i) with payment for the Option Investor Shares to be made to the Company by wire transfer of immediately available funds on the Option Closing Date and (ii) with delivery of the Option Investor Shares registered, as applicable, in the name of the Investor or its designees and otherwise free and clear of all liens, with any transfer or stamp taxes duly paid by the Company.

 

III.

Representations, Warranties and Covenants

The Company hereby represents and warrants to and agrees with the Investor to all the same representations and warranties contained in Section 1 and the covenants contained in Section 5 of the Underwriting Agreement mutatis mutandis to the same extent as if such representations and warranties and covenants were set forth herein for the benefit of the Investor instead of the underwriters party to the Underwriting Agreement (except that references to the Underwriting Agreement therein shall be references to this Agreement and references to the Underwritten Securities and Option Securities thereunder shall be references to the Firm Investor Shares and Option Investor Shares, respectively).

 

2


The Investor hereby represents and warrants to the Company that it (i) is acquiring the securities to be purchased pursuant to this Agreement (the “Purchased Securities”) for its own account solely for the purpose of investment and not with a view to, or for resale in connection with, any distribution of such Purchased Securities or any interest therein and (ii) has been provided an opportunity to ask questions of and receive answers from representatives of the Company concerning the terms and conditions of this Agreement and the purchase of the Purchased Securities contemplated hereby.

 

IV.

Additional Covenants of the Company

Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company agrees to pay or cause to be paid the reasonable fees and expenses of Simpson Thacher & Bartlett LLP, counsel to the Invus Entities, relating to the Public Offering and the transactions contemplated by this Agreement within 15 days of the submission of any invoice with respect thereto.

 

V.

Conditions to the Investor’s Obligations to Purchase the Purchased Securities

The obligations of the Investor hereunder to purchase the Firm Investor Shares and the Option Investor Shares, as the case may be, from the Company, and of the Company to sell the Firm Investor Shares and the Option Investor Shares, as the case may be, to the Investor, will be subject to the satisfaction or waiver of the following conditions on or prior to the Firm Closing Date and the Option Closing Date, as the case may be:

(a) The satisfaction by the Company of the conditions set forth in Section 6 of the Underwriting Agreement (other than clause (l) thereunder);

(b) The substantially concurrent closing of the sale of the Firm Shares and the Option Shares, as the case may be, on the terms set forth in the Underwriting Agreement;

(c) The delivery to the Investor of opinions of counsel to the Company by the same counsel as set forth in Sections 6(b), (c) and (d) of the Underwriting Agreement in the form and substance acceptable to the Investor; and

(d) The delivery to the Investor of the officer’s certificate contemplated by Section 6(f) of the Underwriting Agreement.

These conditions are for the Investor’s sole benefit and may be waived by the Investor in its sole discretion.

 

VI.

Termination

This Agreement shall automatically terminate upon any termination of the Underwriting Agreement.

 

3


VII.

Miscellaneous

(a) The Company hereby agrees to indemnify and hold harmless each of the Invus Entities and each of their respective affiliates, directors, officers, agents and employees and each person, if any, who controls the Invus Entities within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the “Indemnitees”) from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) arising out of or relating to any of the transactions contemplated by this Agreement. For the avoidance of doubt and notwithstanding the foregoing, the Company shall not be obligated to indemnify and hold harmless the Indemnitees from and against any losses resulting from a decrease in the trading price of their Common Stock.

(b) The provisions of Sections 13, 14, 17, 18 and 19 of the Underwriting Agreement are incorporated herein by reference and shall apply to this Agreement mutatis mutandis.

(c) This Agreement may not be amended or modified except by an instrument in writing signed by, or on behalf of, the parties hereto.

(d) This Agreement shall be deemed to satisfy (i) any requirements of the Invus Entities, as applicable, to provide written notice to the Company in accordance with Section 12.03 of the Certificate of Incorporation in order to be considered a “Covered Stockholder”, (ii) the Company’s obligations under the Certificate of Incorporation with respect to the delivery of a “Notice of Issuance” with respect to the Firm Shares and any Option Shares and (iii) the Company’s obligations under the Registration Rights Agreement to provide written notice of the Public Offering, and shall, to the extent the Company issues and delivers the Firm Shares and any Option Shares as contemplated by this Agreement, constitute the Invus Entities’ waiver of rights pursuant to each of Section 12.01 of the Certificate of Incorporation and Section 2.02 of the Registration Rights Agreement, as applicable, with respect to the Firm Shares and the Option Shares.

(e) This Agreement may be executed and delivered in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

(f) All notices and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by fax, by electronic transmission, by a recognized overnight courier service or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this clause (f)):

if to any of the Invus Entities:

Artal International S.C.A.

44 rue de la Vallée

L-2661 Luxembourg

Luxembourg

Attention: Anne Goffard

and

 

4


The Invus Group, L.L.C.

750 Lexington Avenue (30th Floor)

New York, New York 10022

Attention: David van Zandt

with a copy to:

Simpson Thacher & Bartlett LLP

425 Lexington Avenue

New York, New York 10017

Attention: Kenneth Wallach, Esq.

        Hui Lin, Esq.

if to the Company:

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Blvd., 11th Floor

The Woodlands, Texas 77381

Attention: President and Chief Executive Officer

with a copy to:

Vinson & Elkins L.L.P.

845 Texas Avenue, Suite 4700

Houston, Texas 77002-6760

Attention: David Palmer Oelman, Esq.

[Signature Page Follows]

 

5


Sincerely,

INVUS, L.P.,

a Bermuda limited partnership

By:   Invus Advisors, L.L.C., its general partner
By:   /s/ Philip Bafundo
Name:   Philip Bafundo
Title:   CFO of the General Partner
ARTAL INTERNATIONAL S.C.A., a Luxembourg partnership limited by shares
By:   Artal International Management S.A., its managing partner
By:   /s/ Anne Goffard
Name:   Anne Goffard
Title:   Managing Director
ARTAL GROUP S.A.
By:   /s/ Anne Goffard
Name:   Anne Goffard
Title:   Déléguée à la gestion journalière
ARTAL INTERNATIONAL MANAGEMENT S.A.
By:   /s/ Anne Goffard
Name:   Anne Goffard
Title:   Managing Director
INVUS ADVISORS, L.L.C.
By:   /s/ Philip Bafundo
Name:   Philip Bafundo
Title:   Chief Financial Officer

Signature Page to Purchase Agreement


INVUS PUBLIC EQUITIES, L.P.
By: Invus Public Equities, LLC, its general partner
By:   /s/ Philip Bafundo
Name:   Philip Bafundo
Title:   Chief Financial Officer
AMAURY WITTOUCK
By:   /s/ Amaury Wittouck
STICHTING ADMINISTRATIEKANTOOR WESTEND
By:   /s/ Amaury Wittouck
Name:   Amaury Wittouck
Title:   Sole Member of the Board
WESTEND S.A.
By:   /s/Anne Goffard
Name:   Anne Goffard
Title:   Managing Director

Signature Page to Purchase Agreement


Accepted and agreed to:
LEXICON PHARMACEUTICALS, INC., a Delaware corporation
By:   /s/ Jeffrey L. Wade
Name:   Jeffrey L. Wade
Title:   President and Chief Financial Officer

Signature Page to Purchase Agreement

EX-10.2 5 d342123dex102.htm EX-10.2 EX-10.2

Exhibit 10.2

EXECUTION VERSION

PURCHASE AGREEMENT

July 27, 2022

Invus US Partners LLC

750 Lexington Avenue (30th Floor)

New York, New York 10022

Attention: Philip J. Bafundo

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Blvd., 11th Floor

The Woodlands, Texas 77381

Attn: President and Chief Executive Officer

Ladies and Gentlemen:

Reference is made to (a) that certain Underwriting Agreement being entered into by Lexicon Pharmaceuticals, Inc. (the “Company”) with the representatives of the underwriters named in Schedule II thereto (the “Underwriters”) concurrently with this Agreement (the “Underwriting Agreement”) providing for the issuance by the Company to the Underwriters (the “Public Offering”) of 16,843,600 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), plus up to 2,526,540 additional shares of Common Stock (the “Option Shares”) that may be issued pursuant to the Underwriters’ option to purchase additional shares of Common Stock provided for in Section 2(b) of the Underwriting Agreement (the “Option”), for sale in a public offering at a price to the public of $2.50 per share (the “Purchase Price”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Underwriting Agreement.

In consideration of the mutual covenants and agreements herein contained, and intending to be legally bound hereby, Invus US Partners LLC (the “Investor”) shall purchase, subject to the terms and conditions herein, (i) 982,600 shares of Common Stock (the “Firm Investor Shares”) and (ii) in the event that the Underwriters exercise the Option, up to 147,390 shares of Common Stock (the “Option Investor Shares”).

 

I.

The Firm Investor Shares

Subject to the satisfaction or waiver of the conditions described in Section V, the Investor hereby agrees to purchase the Firm Investor Shares from the Company at the Purchase Price. The total purchase price for the Firm Investor Shares shall be equal to $2,456,500.

The closing of the sale of the Firm Investor Shares shall take place concurrently with the closing of the sale of the Firm Shares under the Underwriting Agreement (the “Firm Closing Date”), (i) with payment for the Firm Investor Shares to be made to the Company by wire transfer of immediately available funds on the Firm Closing Date and (ii) with delivery of the Firm Investor Shares registered, as applicable, in the name of the Investor or its designees and otherwise free and clear of all liens, with any transfer or stamp taxes duly paid by the Company.


II.

The Option Investor Shares

In the event that the Underwriters exercise the Option, the Investor shall have the option to purchase, at the Purchase Price, a number of Option Investor Shares from the Company, determined by multiplying 147,390 by a fraction, the numerator of which shall be the number of Option Shares as to which the Underwriters exercise the Option and the denominator of which shall be the maximum number of Option Shares subject to the Option, rounded down to the nearest whole number.

The closing of the sale of the Option Investor Shares purchased pursuant to this Section II shall take place concurrently with the closing of the sale of the Option Shares, as to which the Underwriters exercise the Option (the “Option Closing Date”), (i) with payment for the Option Investor Shares to be made to the Company by wire transfer of immediately available funds on the Option Closing Date and (ii) with delivery of the Option Investor Shares registered, as applicable, in the name of the Investor or its designees and otherwise free and clear of all liens, with any transfer or stamp taxes duly paid by the Company.

 

III.

Representations, Warranties and Covenants

The Company hereby represents and warrants to and agrees with the Investor to all the same representations and warranties contained in Section 1 and the covenants contained in Section 5 of the Underwriting Agreement mutatis mutandis to the same extent as if such representations and warranties and covenants were set forth herein for the benefit of the Investor instead of the underwriters party to the Underwriting Agreement (except that references to the Underwriting Agreement therein shall be references to this Agreement and references to the Underwritten Securities and Option Securities thereunder shall be references to the Firm Investor Shares and Option Investor Shares, respectively).

The Investor hereby represents and warrants to the Company that it (i) is acquiring the securities to be purchased pursuant to this Agreement (the “Purchased Securities”) for its own account solely for the purpose of investment and not with a view to, or for resale in connection with, any distribution of such Purchased Securities or any interest therein and (ii) has been provided an opportunity to ask questions of and receive answers from representatives of the Company concerning the terms and conditions of this Agreement and the purchase of the Purchased Securities contemplated hereby.

 

IV.

Additional Covenants of the Company

Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company agrees to pay or cause to be paid the reasonable fees and expenses of Simpson Thacher & Bartlett LLP, counsel to the Investor, relating to the Public Offering and the transactions contemplated by this Agreement within 15 days of the submission of any invoice with respect thereto.

 

2


V.

Conditions to the Investor’s Obligations to Purchase the Purchased Securities

The obligations of the Investor hereunder to purchase the Firm Investor Shares and the Option Investor Shares, as the case may be, from the Company, and of the Company to sell the Firm Investor Shares and the Option Investor Shares, as the case may be, to the Investor, will be subject to the satisfaction or waiver of the following conditions on or prior to the Firm Closing Date and the Option Closing Date, as the case may be:

(a) The satisfaction by the Company of the conditions set forth in Section 6 of the Underwriting Agreement (other than clause (l) thereunder);

(b) The substantially concurrent closing of the sale of the Firm Shares and the Option Shares, as the case may be, on the terms set forth in the Underwriting Agreement;

(c) The delivery to the Investor of opinions of counsel to the Company by the same counsel as set forth in Sections 6(b), (c) and (d) of the Underwriting Agreement in the form and substance acceptable to the Investor; and

(d) The delivery to the Investor of the officer’s certificate contemplated by Section 6(f) of the Underwriting Agreement.

These conditions are for the Investor’s sole benefit and may be waived by the Investor in its sole discretion.

 

VI.

Termination

This Agreement shall automatically terminate upon any termination of the Underwriting Agreement.

 

VII.

Miscellaneous

(a) The Company hereby agrees to indemnify and hold harmless the Investor and each of its respective affiliates, directors, officers, agents and employees and each person, if any, who controls the Investor within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the “Indemnitees”) from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses reasonably incurred in connection with defending or investigating any such action or claim) arising out of or relating to any of the transactions contemplated by this Agreement. For the avoidance of doubt and notwithstanding the foregoing, the Company shall not be obligated to indemnify and hold harmless the Indemnitees from and against any losses resulting from a decrease in the trading price of their Common Stock.

(b) The provisions of Sections 13, 14, 17, 18 and 19 of the Underwriting Agreement are incorporated herein by reference and shall apply to this Agreement mutatis mutandis.

(c) This Agreement may not be amended or modified except by an instrument in writing signed by, or on behalf of, the parties hereto.

 

3


(d) This Agreement may be executed and delivered in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

(e) All notices and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by fax, by electronic transmission, by a recognized overnight courier service or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this clause (e)):

if to the Investor:

The Invus Group, L.L.C.

750 Lexington Avenue (30th Floor)

New York, New York 10022

Attention: David van Zandt

with a copy to:

Simpson Thacher & Bartlett LLP

425 Lexington Avenue

New York, New York 10017

Attention: Kenneth Wallach, Esq.

Hui Lin, Esq.

if to the Company:

Lexicon Pharmaceuticals, Inc.

2445 Technology Forest Blvd., 11th Floor

The Woodlands, Texas 77381

Attention: President and Chief Executive Officer

with a copy to:

Vinson & Elkins L.L.P.

845 Texas Avenue, Suite 4700

Houston, Texas 77002-6760

Attention: David Palmer Oelman, Esq.

[Signature Page Follows]

 

4


Sincerely,
INVUS US PARTNERS LLC
By:   /s/ Philip Bafundo
Name:   Philip Bafundo
Title:   Authorized Person

 

Accepted and agreed to:

LEXICON PHARMACEUTICALS, INC.,

a Delaware corporation

By:   /s/ Jeffrey L. Wade
Name: Jeffrey L. Wade
Title: President and Chief Financial Officer

Signature Page to Purchase Agreement

EX-99.1 6 d342123dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

NEWS RELEASE

FOR IMMEDIATE RELEASE

LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

The Woodlands, Texas, July 27, 2022 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001 (the “Common Stock”). In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of Common Stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Citigroup and Piper Sandler are acting as joint book-running managers for the proposed offering.

Lexicon currently intends to use the net proceeds that it will receive from the offering, together with its existing cash and cash equivalents and short-term investments, for (i) funding pre-commercial and commercial launch activities for sotagliflozin in heart failure; (ii) funding continued development of sotagliflozin in heart failure and LX9211 in neuropathic pain; and (iii) working capital and other general corporate purposes.

A shelf registration statement on Form S-3 relating to the proposed offering was filed with the U.S. Securities and Exchange Commission (“SEC”) on August 6, 2021 and declared effective by the SEC on September 14, 2021 (File No. 333-258564). A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146, or by email at prospectus@citi.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attn: Prospectus Department, by telephone at 1-800-747-3924, or by email at prospectus@psc.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000 program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications.


Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements, including, without limitation, statements about the completion and timing of the offering and the grant of the option to the underwriters to purchase additional shares, are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, quarterly report on Form 10-Q for the quarter ended March 31, 2022 and other subsequent disclosure documents filed with the SEC. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Inquiries:

Mike Kelly

Lexicon Pharmaceuticals

mkelly@lexpharma.com

EX-99.2 7 d342123dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

 

LOGO

NEWS RELEASE

FOR IMMEDIATE RELEASE

LEXICON ANNOUNCES PRICING OF $85.0 MILLION PUBLIC OFFERING AND

CONCURRENT PRIVATE PLACEMENT

The Woodlands, Texas, July 28, 2022 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the “Common Stock”). The shares of Common Stock are being offered at a public offering price of $2.50 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be approximately $42.1 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Lexicon has granted the underwriters a 30-day option to purchase up to an additional 2,526,540 shares of Common Stock (the “Option Shares”) at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about August 1, 2022, subject to the satisfaction of customary closing conditions.

Lexicon currently intends to use the net proceeds that it will receive from the public offering and the concurrent private placement, together with its existing cash and cash equivalents and short-term investments, for (i) funding pre-commercial and commercial launch activities for sotagliflozin in heart failure; (ii) funding continued development of sotagliflozin in heart failure and LX9211 in neuropathic pain; and (iii) working capital and other general corporate purposes.

Citigroup and Piper Sandler are acting as joint book-running managers for the public offering.

In addition to the shares being sold in the underwritten public offering, Lexicon has agreed to sell 17,156,400 shares of its Common Stock to raise gross proceeds of approximately $42.9 million in a concurrent private placement at $2.50 per share to one or more affiliates (the “Private Placement Purchasers”) of Invus, L.P., Lexicon’s largest stockholder. The Private Placement Purchasers will have the option to purchase, on a pro rata basis, up to an additional 2,573,460 shares of Common Stock at the public offering price of $2.50 per share to the extent the underwriters exercise their option to purchase the Option Shares. The sale of these shares of Common Stock will not be registered under the Securities Act of 1933, as amended (the “Securities Act”). The concurrent private placement is also scheduled to close on August 1, 2022, subject to the satisfaction of customary closing conditions. The closing of the underwritten public offering is not conditioned on the closing of the concurrent private placement.

A shelf registration statement on Form S-3 relating to the underwritten public offering was filed with the U.S. Securities and Exchange Commission (“SEC”) on August 6, 2021 and declared effective by the SEC on September 14, 2021. The shares of Common Stock proposed to be issued in the concurrent private placement have not been registered under the Securities Act, or the


securities laws of any state or other jurisdiction in the United States, and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States except pursuant to registration under the Securities Act, or an applicable exemption from the registration requirements of the Securities Act and, in each case, in compliance with other applicable securities laws. A preliminary prospectus supplement and accompanying prospectus relating to the underwritten public offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying prospectus may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146, or by email at prospectus@citi.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attn: Prospectus Department, by telephone at 1-800-747-3924, or by email at prospectus@psc.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000 program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements, including, without limitation, statements about the completion and timing of the public offering and the concurrent private placement, are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2021, quarterly report on Form 10-Q for the quarter ended March 31, 2022 and other subsequent disclosure documents filed with the SEC. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

 

Page 2


For Inquiries:

Mike Kelly

Lexicon Pharmaceuticals

mkelly@lexpharma.com

 

Page 3

EX-99.3 8 d342123dex993.htm EX-99.3 EX-99.3

Exhibit 99.3

LOGO

NEWS RELEASE

FOR IMMEDIATE RELEASE

LEXICON ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR SOTAGLIFLOZIN TO TREAT HEART FAILURE

NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin

in Almost 12,000 People

The Woodlands, Texas, July 27, 2022Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of heart failure. The FDA assigned a standard review for the NDA filing with a Prescription Drug User Fee Act (PDUFA) target action date in May 2023.

“This is an important step in potentially bringing sotagliflozin to market as a new treatment for heart failure,” said Lonnel Coats, Lexicon’s chief executive officer. “Informed by our regulatory discussions, we are seeking a broad heart failure label in the NDA encompassing heart failure patients with and without diabetes, and believe that the results of SOLOIST-WHF in patients admitted for recent worsening heart failure will be an important element distinguishing our proposed label. We look forward to engaging with the FDA during the review process to bring this potential new treatment to market by the middle of next year.”

The NDA is supported by the results from the Phase 3 SOLOIST-WHF clinical study in patients with type 2 diabetes who had recently been hospitalized for worsening heart failure and the Phase 3 SCORED clinical study in patients with type 2 diabetes, chronic kidney disease and risks for cardiovascular disease. In the NDA, Lexicon is seeking that sotagliflozin be indicated to:

 

   

Reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure, including those with acute or worsening heart failure.

 

   

Reduce the risk of cardiovascular death, hospitalization for heart failure, urgent heart failure visit, nonfatal myocardial infarction, and nonfatal stroke in adults with type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors, including a history of heart failure.

About the SOLOIST-WHF and SCORED Studies

SOLOIST-WHF was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 people with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in people treated with sotagliflozin compared with placebo.


SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 people with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m2 of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in people treated with sotagliflozin compared with placebo.

Both SOLOIST-WHF and SCORED achieved their respective primary endpoints, with overall tolerability similar to placebo across both trials. Results from both studies were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.”

About Sotagliflozin

Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, type 1 and type 2 diabetes, and chronic kidney disease in fourteen Phase 3 clinical studies involving approximately 20,000 patients.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000 program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” within the meaning of the federal securities laws, including, but not limited to, statements relating to the timing, clinical development of, regulatory filings and proposed label for, and potential therapeutic and commercial potential of sotagliflozin. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2021, quarterly report on Form 10-Q for the quarter ended March 31, 2022 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

 

Page 2


For Inquiries:

Mike Kelly

Lexicon Pharmaceuticals

mkelly@lexpharma.com

 

Page 3

EX-101.SCH 9 lxrx-20220727.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 10 lxrx-20220727_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 11 lxrx-20220727_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 g342123g0728071748076.jpg GRAPHIC begin 644 g342123g0728071748076.jpg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g342123g0728083921918.jpg GRAPHIC begin 644 g342123g0728083921918.jpg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g342123g0728194849196.jpg GRAPHIC begin 644 g342123g0728194849196.jpg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g342123g0729025542233.jpg GRAPHIC begin 644 g342123g0729025542233.jpg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g342123g0729025542389.jpg GRAPHIC begin 644 g342123g0729025542389.jpg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end XML 17 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jul. 27, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001062822
Document Type 8-K
Document Period End Date Jul. 27, 2022
Entity Registrant Name Lexicon Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 000-30111
Entity Tax Identification Number 76-0474169
Entity Address, Address Line One 2445 Technology Forest Blvd.
Entity Address, Address Line Two 11th Floor
Entity Address, City or Town The Woodlands
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77381
City Area Code (281)
Local Phone Number 863-3000
Security 12b Title Common stock, par value $0.001
Trading Symbol LXRX
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false

XML 18 d342123d8k_htm.xml IDEA: XBRL DOCUMENT 0001062822 2022-07-27 2022-07-27 false 0001062822 8-K 2022-07-27 Lexicon Pharmaceuticals, Inc. DE 000-30111 76-0474169 2445 Technology Forest Blvd. 11th Floor The Woodlands TX 77381 (281) 863-3000 Common stock, par value $0.001 LXRX NASDAQ false false false false false EXCEL 19 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 20 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 21 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 22 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d342123d8k.htm d342123dex101.htm d342123dex102.htm d342123dex11.htm d342123dex51.htm d342123dex991.htm d342123dex992.htm d342123dex993.htm lxrx-20220727.xsd lxrx-20220727_lab.xml lxrx-20220727_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 24 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d342123d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d342123d8k.htm" ] }, "labelLink": { "local": [ "lxrx-20220727_lab.xml" ] }, "presentationLink": { "local": [ "lxrx-20220727_pre.xml" ] }, "schema": { "local": [ "lxrx-20220727.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lxrx", "nsuri": "http://www.lexpharma.com/20220727", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d342123d8k.htm", "contextRef": "duration_2022-07-27_to_2022-07-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d342123d8k.htm", "contextRef": "duration_2022-07-27_to_2022-07-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lexpharma.com//20220727/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 25 0001193125-22-206851-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-206851-xbrl.zip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end